For the quarter ending 2025-09-30, ZVSA made $19,674,209 in revenue. -$19,805,559 in net income. Net profit margin of -100.67%.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development | 365,053 | 409,937 | ||
| General and administrative | 1,739,174 | 1,634,195 | ||
| Impairment of in-process research and development | 18,647,903 | - | ||
| Total operating expenses | 20,752,130 | 2,044,132 | ||
| Loss from operations | -20,752,130 | -2,044,132 | ||
| Interest expense | -131,350 | -130,036 | ||
| Change in fair value of equity payable | -226,262 | 37,149 | ||
| Pre-tax net loss | -20,657,218 | -2,211,317 | ||
| Income tax benefit (provision) | -851,659 | 0 | ||
| Net loss | -19,805,559 | -2,211,317 | ||
| Basic | -2.56 | -0.46 | ||
| Basic | 7,740,678 | 4,814,115 | ||
| Diluted | -2.56 | -0.46 | ||
| Diluted | 7,740,678 | 4,814,115 | ||
ZyVersa Therapeutics, Inc. (ZVSA)
ZyVersa Therapeutics, Inc. (ZVSA)